NCT06616103

Brief Summary

This study aims to evaluate diagnostic performance of CT attenuation parameters acquired using deep learning algorithm in assessing hepatic steatosis and fibrosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
111

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2024

Completed
7 days until next milestone

Study Start

First participant enrolled

September 26, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 27, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2025

Completed
Last Updated

September 27, 2024

Status Verified

September 1, 2024

Enrollment Period

11 months

First QC Date

September 19, 2024

Last Update Submit

September 24, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • diagnostic performance of CT attenuatio parameters in assessing hepatic steatosis and fibrosis

    diagnostic performance of CT attenuatio parameters in assessing hepatic steatosis and fibrosis using MRI-PDFF and MR elastography as reference standards

    At the time of enrollment

Secondary Outcomes (1)

  • Consistency between MRI-derived body composition data and CT-derived data

    At the time of enrollment

Interventions

noncontrast abdominal CT

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with chronic hepatitis B who follow up at Seoul National University Hospital having no history of hepatic malignancies

You may qualify if:

  • chronic hepatitis B
  • no chronic liver disease other than chronic hepatitis B
  • Body mass index \>= 23

You may not qualify if:

  • pregnant women
  • unable to perform MRI examinations due to claustrophobia or metallic foreign body
  • suspicious hepatic malignancy on previous imaging studies
  • history of local treatment for hepatic lesions
  • history of surgery or catheter insertion of liver or spleen

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, 03080, South Korea

Location

MeSH Terms

Conditions

Hepatitis B, ChronicFatty LiverFibrosis

Interventions

Tomography, X-Ray Computed

Condition Hierarchy (Ancestors)

Hepatitis BBlood-Borne InfectionsCommunicable DiseasesInfectionsHepadnaviridae InfectionsDNA Virus InfectionsVirus DiseasesHepatitis, Viral, HumanHepatitis, ChronicHepatitisLiver DiseasesDigestive System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Image Interpretation, Computer-AssistedDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisRadiographic Image EnhancementImage EnhancementPhotographyRadiographyTomography, X-RayTomography

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical assistant professor

Study Record Dates

First Submitted

September 19, 2024

First Posted

September 27, 2024

Study Start

September 26, 2024

Primary Completion

August 31, 2025

Study Completion

August 31, 2025

Last Updated

September 27, 2024

Record last verified: 2024-09

Locations